Showcasing AI-Powered Lung Cancer Screening Innovations Backed by Pivotal Clinical Studies
Median Technologies a leading innovator in artificial intelligence (AI)-driven medical imaging and a global provider of advanced central imaging services for oncology drug development, has announced its participation at the Radiological Society of North America (RSNA) 2025 Annual Meeting. The event will take place at McCormick Place in Chicago, Illinois, from November 30 to December 4, 2025. At this year’s meeting, Median will highlight its latest advancements in AI-powered diagnostic technologies, including its flagship Software as a Medical Device (SaMD), eyonis® LCS, an AI solution designed to transform lung cancer screening and early diagnosis.
Throughout the event, representatives from the Median iCRO and eyonis® teams will be available at Booth #5438, located in the AI Showcase area of the South Hall, Level 3. The team will be on-site from November 30 through December 3, coinciding with the technical exhibit schedule. They will present the most recent innovations in lung cancer screening solutions and update attendees on the company’s progress in AI-enhanced central imaging services for oncology clinical trials.
Advancing Early Detection With eyonis® LCS
The centerpiece of Median’s presence at RSNA 2025 will be eyonis® LCS, an AI-driven Software as a Medical Device specifically developed to address two persistent challenges in lung cancer screening programs: improving diagnostic accuracy and enhancing operational efficiency. Lung cancer remains the leading cause of cancer-related deaths worldwide, largely due to late-stage diagnosis. Earlier detection significantly increases the likelihood of effective treatment, and AI-driven tools like eyonis® LCS aim to close the gaps associated with traditional low-dose CT (LDCT) interpretation.
eyonis® LCS has undergone extensive clinical evaluation through two pivotal studies—REALITY (ClinicalTrials.gov ID: NCT06576232) and RELIVE (ClinicalTrials.gov ID: NCT06751576). These studies were required for regulatory submissions in both the United States and Europe and have now been successfully completed. Leveraging the data generated from these trials, Median Technologies submitted its U.S. FDA 510(k) clearance application for eyonis® LCS on May 13, 2025, followed by its European CE mark application on June 30, 2025. Regulatory reviews are currently underway, and eyonis® LCS is not yet commercially available in either region pending final approvals.
Thomas Bonnefont, COO and CCO for eyonis® at Median Technologies, underscored the transformative potential of the software, stating, “We are excited to share the latest eyonis® LCS data with the global radiology community at the RSNA 2025 Annual Meeting. eyonis® LCS enables earlier diagnosis, streamlines workflows, promotes program adherence, and ultimately supports better patient outcomes. Our Software as a Medical Device is poised to be a key driver in accelerating the global adoption of lifesaving screening programs.”
Bonnefont also highlighted the broader implications for healthcare systems worldwide. In the United States, lung cancer screening is now well established, and procedures incorporating AI for quantitative tissue analysis on LDCT scans currently receive a reimbursement rate of $650 per use. Meanwhile, European nations continue to expand structured lung cancer screening initiatives. Germany, for example, is preparing to launch its national screening program in April 2026. As these programs grow, AI-driven platforms such as eyonis® LCS stand to play a critical role in scalability, efficiency, and clinical accuracy.
Scientific & Educational Contributions at RSNA 2025
Median Technologies will contribute to RSNA 2025’s scientific and educational agenda through two featured presentations, each addressing key innovations in AI-based lung cancer screening and diagnostic imaging.
Peer-Reviewed Scientific Presentation
“Rethinking Lung Cancer Screening: Longitudinal AI/ML Diagnostics Beyond Nodule Size Growth”
- Date: Wednesday, December 3
- Time: 3:00 PM – 4:00 PM CT
- Session: W7-SSCH07 Chest Imaging (Nodules)
- Location: South Building, Level 5, Room S501
This scientific presentation will delve into advanced AI/ML methodologies that move beyond traditional metrics such as nodule size. Instead, eyonis® employs longitudinal assessments and multi-dimensional diagnostic parameters to improve accuracy in identifying early-stage cancer. The session will focus on how AI can reduce false positives, refine clinical decision-making, and enhance the consistency of screening programs over time.
AI Theater Presentation
“eyonis® LCS: Transforming Lung Cancer Screening Through AI-Powered Early Detection & Diagnosis”
- Date: Sunday, November 30
- Time: 12:30 PM – 12:50 PM CT
- Session: AI-Theater Presentation (IT5-AI105)
- Location: AI Theater, Booth #5536, South Hall, Level 3
In this 20-minute spotlight session, the eyonis® team will introduce attendees to the system’s technical framework, clinical performance metrics, and real-world applications. The presentation will emphasize how the software integrates into radiology workflows, supporting clinicians in making faster, more accurate diagnoses while reducing unnecessary follow-up procedures.
Driving Innovation in Oncology Imaging Services
Beyond its advancements in lung cancer screening, Median Technologies will also share updates on its iCRO (imaging Contract Research Organization) services. The company remains a global leader in providing centralized imaging solutions for oncology drug developers. With the integration of AI-powered analytics, Median’s iCRO platform supports precise and reliable assessments within clinical trials—an increasingly vital component as novel cancer therapies advance through research pipelines.
By combining the strengths of traditional imaging expertise with cutting-edge AI tools, Median seeks to redefine standards in trial imaging, enabling pharmaceutical companies to evaluate treatment responses more effectively and accelerate the development of next-generation cancer therapeutics.
Looking Ahead
As lung cancer screening programs continue to expand across the globe, the need for accurate, efficient, and scalable diagnostic tools is more urgent than ever. Median Technologies’ participation at RSNA 2025 highlights its commitment to addressing these challenges through scientifically validated, AI-powered innovations.
With regulatory reviews for eyonis® LCS progressing and clinical data demonstrating strong potential to improve outcomes, the company stands poised to play a foundational role in the future of cancer screening and oncology imaging. The RSNA Annual Meeting offers an ideal platform for Median to engage with radiologists, researchers, healthcare systems, and industry leaders—and to showcase how AI can truly reshape the landscape of early cancer detection.
About eyonis® LCS: eyonis® Lung Cancer Screening (LCS) is an artificial intelligence AI-based computer aided detection and diagnosis (CADe/CADx) system, or Software as a Medical Device (SaMD) that uses machine learning to help analyze imaging data generated with low dose computed tomography (LDCT). eyonis® LCS empowers radiologists to diagnose lung cancer at its earliest, most treatable stages—when curative options remain possible for many patients. eyonis® LCS has been the subject of two pivotal studies required for marketing approvals in the U.S. and Europe: REALITY both of which have been successfully completed. Based on these pivotal data, Median Technologies submitted U.S. application for 510(k) clearance of eyonis® LCS on May 13th, 2025, and European application for CE mark on June 30th, 2025. eyonis® LCS is currently under review for FDA 510(k) clearance and CE marking and is not yet for sale in the US and in Europe.
About RSNA Annual Meeting: The Radiological Society of North America Annual Meeting is the largest medical imaging conference in the world, featuring over 300 educational courses and more than 2,800 scientific presentations covering every subspecialty. RSNA 2025 is expecting approximately 50,000 medical imaging professionals, representing over 120 countries. RSNA hosts the largest medical equipment exhibition, featuring products and services from almost 700 manufacturers, suppliers and developers from innovative startups to industry giants. For more information about the RSNA 2025 Annual Meeting
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme
source link : https://www.businesswire.com
